A clinical trial evaluating safety and efficacy of the MEK1/2 inhibitor, binimetinib, is underway in children with glioma and other tumors containing KIAA1549–BRAF fusions or other activating mutations with some early signals of efficacy (Table 3) [67]. The gene discussed is BRAF; the disease is central nervous system cancer.